{"entity":{"id":"nct03441113","kind":"trial","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","aka":[],"tldr":"A phase 2 trial of MMB in myeloproliferative neoplasms, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Extended Access of Momelotinib in Adults With Myelofibrosis is a phase 2 interventional study registered as NCT03441113 by GlaxoSmithKline, with 237 participants enrolled, started 2018-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: MMB.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03441113","url":"https://clinicaltrials.gov/study/NCT03441113"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03441113","phase":"2","setting":"Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","sponsor":"GlaxoSmithKline","enrolled":237,"outcomes":[]},"route":"/trials/nct03441113/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}